HK1250029A1 - 具有雙環結構的多巴胺d3受體拮抗劑 - Google Patents

具有雙環結構的多巴胺d3受體拮抗劑

Info

Publication number
HK1250029A1
HK1250029A1 HK18109519.3A HK18109519A HK1250029A1 HK 1250029 A1 HK1250029 A1 HK 1250029A1 HK 18109519 A HK18109519 A HK 18109519A HK 1250029 A1 HK1250029 A1 HK 1250029A1
Authority
HK
Hong Kong
Prior art keywords
dopamine
receptor antagonists
bicyclo
moiety
bicyclo moiety
Prior art date
Application number
HK18109519.3A
Other languages
English (en)
Inventor
Susanna Cremonesi
Fabrizio Micheli
Teresa Semeraro
Luca Tarsi
Original Assignee
Indivior Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1513871.2A external-priority patent/GB201513871D0/en
Priority claimed from GBGB1518125.8A external-priority patent/GB201518125D0/en
Application filed by Indivior Uk Ltd filed Critical Indivior Uk Ltd
Publication of HK1250029A1 publication Critical patent/HK1250029A1/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53831,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Addiction (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK18109519.3A 2015-08-05 2018-07-23 具有雙環結構的多巴胺d3受體拮抗劑 HK1250029A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1513871.2A GB201513871D0 (en) 2015-08-05 2015-08-05 Bicyclo dopamine D3 receptor antagonists
GBGB1518125.8A GB201518125D0 (en) 2015-10-13 2015-10-13 Dopamine D3 receptor antagonist having a bicyclo moiety
PCT/IB2016/054708 WO2017021920A1 (en) 2015-08-05 2016-08-04 Dopamine d3 receptor antagonists having a bicyclo moiety

Publications (1)

Publication Number Publication Date
HK1250029A1 true HK1250029A1 (zh) 2018-11-23

Family

ID=56801657

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18109519.3A HK1250029A1 (zh) 2015-08-05 2018-07-23 具有雙環結構的多巴胺d3受體拮抗劑

Country Status (11)

Country Link
US (2) US10273244B2 (zh)
EP (1) EP3331886B1 (zh)
AU (1) AU2016303558B2 (zh)
CA (1) CA2992820C (zh)
DK (1) DK3331886T3 (zh)
ES (1) ES2821896T3 (zh)
HK (1) HK1250029A1 (zh)
IL (1) IL256914B (zh)
NZ (1) NZ739139A (zh)
WO (1) WO2017021920A1 (zh)
ZA (1) ZA201800483B (zh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016303558B2 (en) 2015-08-05 2020-08-06 Indivior Uk Limited Dopamine D3 receptor antagonists having a bicyclo moiety
US10870660B2 (en) 2016-07-28 2020-12-22 Shionogi & Co., Ltd. Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect
WO2019084075A1 (en) * 2017-10-24 2019-05-02 The Trustees Of The University Of Pennsylvania DOPAMINE RECEPTOR SELECTIVE ANTAGONISTS AND METHODS OF USING THE SAME
US11447484B2 (en) 2018-01-26 2022-09-20 Shionogi & Co., Ltd. Cyclic compound having dopamine D3 receptor antagonistic effect
BR112020014875A2 (pt) 2018-01-26 2020-12-08 Shionogi & Co., Ltd. Composto cíclico condensado tendo antagonismo de receptor de dopamina d3
EP3758695A4 (en) 2018-02-28 2021-10-06 The Trustees Of The University Of Pennsylvania POLY (AD-RIBOSE) DEPENDENT CYTOTOXIC AGENTS LOW AFFINITY POLYMERASE-1
EP3608326A1 (en) 2018-08-10 2020-02-12 Irbm S.P.A. Tricyclic inhibitors of hepatitis b virus
EP3741762A1 (en) 2019-05-23 2020-11-25 Irbm S.P.A. Oxalamido-substituted tricyclic inhibitors of hepatitis b virus
EP3825318A1 (en) 2019-11-25 2021-05-26 Promidis S.r.l. Oxalamido-substituted tricyclic inhibitors of hepatitis b virus
UY38705A (es) 2019-05-23 2020-12-31 Irbm S P A Inhibidores tricíclicos sustituidos con oxalamido del virus de hepatitis b
CN110684028B (zh) * 2019-10-28 2021-10-26 上海阿拉丁生化科技股份有限公司 一种2,6-二氮杂双环[3,3,0]辛烷类化合物的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4341403A1 (de) * 1993-12-04 1995-06-08 Basf Ag N-substituierte 3-Azabicycloalkan-Derivate, ihre Herstellung und Verwendung
US5541217A (en) 1995-05-17 1996-07-30 Ortho Pharmaceutical Corporation 4-arylcyclopenta[c]pyrrole analgesics
KR101143718B1 (ko) * 2004-02-23 2012-07-05 글락소 그룹 리미티드 도파민 d3 수용체의 조절제로서 유용한 아자비시클로(3.1.0) 헥산 유도체
GB0507680D0 (en) * 2005-04-15 2005-05-25 Glaxo Group Ltd Compounds
US9540324B2 (en) * 2013-09-26 2017-01-10 Luc Therapeutics, Inc. Selective octahydro-cyclopenta[C] pyrrole negative modulators of NR2B
CN106659715A (zh) * 2013-12-20 2017-05-10 药物发现研究所 取代的氨基三唑及其使用方法
AU2016303558B2 (en) 2015-08-05 2020-08-06 Indivior Uk Limited Dopamine D3 receptor antagonists having a bicyclo moiety

Also Published As

Publication number Publication date
IL256914A (en) 2018-03-29
ZA201800483B (en) 2019-07-31
WO2017021920A1 (en) 2017-02-09
AU2016303558B2 (en) 2020-08-06
AU2016303558A1 (en) 2018-02-08
EP3331886B1 (en) 2020-07-15
US20190194225A1 (en) 2019-06-27
ES2821896T3 (es) 2021-04-28
DK3331886T3 (da) 2020-08-24
US20180222918A1 (en) 2018-08-09
US10273244B2 (en) 2019-04-30
CA2992820A1 (en) 2017-02-09
EP3331886A1 (en) 2018-06-13
US10584135B2 (en) 2020-03-10
IL256914B (en) 2021-03-25
CA2992820C (en) 2022-08-16
NZ739139A (en) 2023-01-27

Similar Documents

Publication Publication Date Title
HK1250029A1 (zh) 具有雙環結構的多巴胺d3受體拮抗劑
HK1231382A1 (zh) 毒蕈碱受體激動劑
IL276400A (en) Dopamine D3 receptor antagonist compounds
IL288907A (en) A pharmaceutical combination containing a selective s1p1 receptor agonist
GB2545234B (en) A dispenser
GB201702617D0 (en) Receptor
IL258606B (en) Dopamine d3 receptor antagonists with a morpholine complex
GB2524637B (en) Triggering workflows from a multifunction device
GB2563436B (en) A device for electrolysis
GB201518125D0 (en) Dopamine D3 receptor antagonist having a bicyclo moiety
SG11201700014XA (en) A gasifier
GB201513871D0 (en) Bicyclo dopamine D3 receptor antagonists
ZA201807767B (en) Angiotensin-1-receptor antagonists
GB201419433D0 (en) Dopamine D3 receptor antagonist compounds
GB201419430D0 (en) Dopamine D3 receptor antagonist compounds
PT3464324T (pt) Antagonistas de recetores da angiotensina-1
GB201701887D0 (en) Receptor
GB201700926D0 (en) Receptor
GB2544238B (en) Attachment device for a tubular member
GB201610785D0 (en) A device for electrolysis
GB201409085D0 (en) Argon is a mu opioid receptor antagonist
GB201410480D0 (en) Sulphate metabolite receptors
GB201409094D0 (en) A dispenser
GB201400207D0 (en) A soap metering device